Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies.

The reactivity of 12 surgically removed uveal melanoma lesions with monoclonal antibodies (MoAb) to 14 membrane-bound and 2 cytoplasmic cutaneous melanoma-associated antigens (MAA), to the 2 subunits of HLA Class I antigens and to the gene products of the HLA-D region was compared with that of cutaneous melanoma lesions and correlated with their histiotype. The membrane-bound determinants defined by the anti-Mr 92,000 and 45,000 MAA MoAb TP39.1, anti-Mr 110,000 MAA MoAb M111, anti-Mr 118,000 MAA MoAb TP36.1, anti-Mr 115,000 MAA MoAb 345.134, anti-ICAM-1 MoAb CL203.4 and anti-Mr 31,000 MAA MoAb M2590, and the cytoplasmic determinants defined by the anti-MAA MoAb 465.12 and 2G-10 display a distribution in uveal melanoma lesions similar to that in cutaneous melanoma lesions. On the other hand, membrane-bound determinants defined by the anti-Mr 100,000 MAA MoAb 376.96, anti-9-O-acetyl-GD3 ganglioside MoAb ME311 and anti-GD2-GD3 ganglioside MoAb ME361 were not detected in the uveal melanoma lesions tested. Furthermore, the membrane-bound determinants defined by the anti-GD3 MoAb R24, anti-nerve growth factor receptor MoAb ME20.4, anti-Mr 97,000 MAA MoAb 140.240, anti-carcinoembryonic antigen MoAb B1.1 and anti-HMW-MAA 149.53, 225.28, and 763.74 have a markedly lower expression in uveal than in cutaneous melanoma lesions. Incubation of uveal melanoma lesions with the pool of the MoAb 149.53, 225.28, and 763.74 recognizing distinct and spatially distant determinants of the HMW-MAA increased the intensity of staining of six lesions and stained four lesions which were not stained by the individual monoclonal antibodies. The distribution of HLA Class I antigens in uveal melanoma lesions resembles that in cutaneous melanoma lesions, since they are expressed in all the lesions of the mixed and epithelioid type but were not detected in those of the spindle type, i.e., the counterparts of nevocellular nevi. HLA Class II antigens are expressed with a lower frequency in uveal than in cutaneous melanoma lesions, since they were detected only in 2 of the 12 lesions. One of them is of the mixed type and the other one of the epithelioid type. Besides HLA antigens the determinants defined by the anti-carcinoembryonic MoAb B1.1, anti-ICAM-1 MoAb CL203.4, and anti-GD3 MoAb R24 displayed a differential distribution in the different histiotypes of uveal melanoma, since they are preferentially expressed in lesions of the mixed and epithelioid type.

[1]  J. Schlom,et al.  Molecular Profile, Tissue Distribution and Prognostic Evaluation of a Human Melanoma-Carcinoma Antigen Recognized by the Murine Monoclonal Antibody B1.1 , 1988, The International journal of biological markers.

[2]  D. Ruiter,et al.  Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma. , 1988, The Journal of investigative dermatology.

[3]  S. Ferrone,et al.  Characterization of a monoclonal antibody-defined human melanoma-associated antigen susceptible to induction by immune interferon. , 1987, Journal of immunology.

[4]  J. Bomanji,et al.  Radioimmunoscintigraphy of ocular melanoma with 99mTc labelled cutaneous melanoma antibody fragments. , 1987, The British journal of ophthalmology.

[5]  D. Ruiter,et al.  Heterogeneous expression of melanoma-associated antigens in uveal melanomas. , 1987, Current eye research.

[6]  S. Ferrone,et al.  Analysis with monoclonal antibodies of the molecular and cellular heterogeneity of human high molecular weight melanoma associated antigen. , 1987, Cancer research.

[7]  D. Elder,et al.  Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. , 1987, Cancer research.

[8]  B. Damato,et al.  Monoclonal antibodies to human primary uveal melanomas demonstrate tumor heterogeneity. , 1986, Investigative ophthalmology & visual science.

[9]  G. Mariani,et al.  Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. , 1986, Cancer research.

[10]  R. Schroff,et al.  Human melanoma-associated antigens: analysis of antigenic heterogeneity by molecular, serologic and flow-cytometric approaches. , 1986, Molecular immunology.

[11]  S. Ferrone,et al.  Gene products of the HLA-D region in normal and malignant tissues of nonlymphoid origin. , 1986, Human immunology.

[12]  R. Folberg,et al.  Tissue distribution and biochemical properties of an ocular melanoma-associated antigen. , 1985, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[13]  D. Elder,et al.  Proton NMR and fast-atom bombardment mass spectrometry analysis of the melanoma-associated ganglioside 9-O-acetyl-GD3. , 1985, The Journal of biological chemistry.

[14]  S. Ferrone,et al.  Distribution of a cross-species melanoma-associated antigen in normal and neoplastic human tissues. , 1985, The Journal of investigative dermatology.

[15]  M. Melamed,et al.  Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. , 1985, Cancer research.

[16]  H. Dienes,et al.  Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues. , 1985, Cancer research.

[17]  S. Ferrone,et al.  Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma. , 1985, Cancer research.

[18]  R. Folberg,et al.  An antimelanoma monoclonal antibody and the histopathology of uveal melanomas. , 1985, Archives of ophthalmology.

[19]  D. Elder,et al.  Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Taniguchi,et al.  Syngeneic monoclonal antibodies against melanoma antigens with species specificity and interspecies cross-reactivity. , 1984, The Journal of investigative dermatology.

[21]  E. Bröcker,et al.  HLA-DR antigen expression in primary melanomas of the skin. , 1984, The Journal of investigative dermatology.

[22]  A. Aguzzi,et al.  The impact of monoclonal antibodies on the study of human malignant melanoma , 1983, Journal of cutaneous pathology.

[23]  S. Larson,et al.  Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. , 1983, The Journal of clinical investigation.

[24]  S. Ferrone,et al.  Double determinant immunoassay to measure a human high-molecular-weight melanoma-associated antigen. , 1983, Cancer research.

[25]  S. Ferrone,et al.  Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. , 1983, Journal of immunology.

[26]  J. Cairncross,et al.  Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets , 1982, The Journal of experimental medicine.

[27]  A. Brickenden,et al.  Human melanoma‐specific oncofetal antigen defined by a mouse monoclonal antibody , 1982, International journal of cancer.

[28]  P. Wernet,et al.  Differential inhibition of HLA-D- or SB-directed secondary lymphoproliferative responses with monoclonal antibodies detecting human Ia-like determinants. , 1982, Journal of immunology.

[29]  S. Ferrone,et al.  A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells. , 1982, Journal of the National Cancer Institute.

[30]  S. Ferrone,et al.  Tissue distribution, molecular profile, and shedding of a cytoplasmic antigen identified by the monoclonal antibody 465.12S to human melanoma cells. , 1982, Cancer research.

[31]  S. Ferrone,et al.  Distribution and molecular characterization of a cell‐surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies , 1981, International journal of cancer.

[32]  V. Quaranta,et al.  Serologic and immunochemical characterization of the specificity of four monoclonal antibodies to distinct antigenic determinants expressed on subpopulations of human Ia-like antigens. , 1981, Journal of immunology.

[33]  L. Old,et al.  Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. Bodmer,et al.  Characterization of a monoclonal anti‐β2‐microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens , 1979, European journal of immunology.

[35]  C. Barnstable,et al.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis , 1978, Cell.

[36]  L. Svennerholm CHROMATOGRAPHlC SEPARATION OF HUMAN BRAIN GANGLIOSIDES * , 1963, Journal of neurochemistry.

[37]  J. Brown,et al.  Difference in cell binding patterns of two monoclonal antibodies recognizing distinct epitopes on a human melanoma-associated oncofetal antigen. , 1987, Molecular immunology.

[38]  S. Ferrone,et al.  Immunohistochemical detection of antigen in human primary and metastatic melanomas by the monoclonal antibody 140.240 and its possible prognostic significance , 1987, Cancer.

[39]  L. Donoso,et al.  Antigenic and cellular heterogeneity of primary uveal malignant melanomas. , 1986, Archives of ophthalmology.

[40]  K. Lloyd Human Tumor Antigens: Detection and Characterization with Monoclonal Antibodies , 1983 .

[41]  F. Bach,et al.  Detection of a novel human class II HLA antigen , 1983, Nature.

[42]  J. Burston Ackerman's Surgical Pathology , 1982 .

[43]  F. Calabi,et al.  Analysis of HLA-DR polymorphism by two-dimensional peptide mapping. , 1981, Proceedings of the National Academy of Sciences of the United States of America.